Author
Listed:
- Valentina Perrone
(CliCon S.r.l. Società Benefit—Health, Economics & Outcomes Research, 40137 Bologna, Italy)
- Melania Dovizio
(CliCon S.r.l. Società Benefit—Health, Economics & Outcomes Research, 40137 Bologna, Italy)
- Diego Sangiorgi
(CliCon S.r.l. Società Benefit—Health, Economics & Outcomes Research, 40137 Bologna, Italy)
- Margherita Andretta
(Azienda ULSS 8 Berica, 36100 Vicenza, Italy)
- Fausto Bartolini
(USL Umbria 2 Terni, 05100 Terni, Italy)
- Arturo Cavaliere
(ASL Viterbo, 01100 Viterbo, Italy)
- Andrea Ciaccia
(Servizio Farmaceutico Territoriale ASL Foggia, 71121 Foggia, Italy)
- Alessandro Chinellato
(Azienda ULSS 3 Serenissima, 30174 Mestre, Italy)
- Alberto Costantini
(ASL Pescara, 65100 Pescara, Italy)
- Stefania Dell’Orco
(ASL Roma 6, 00041 Albano Laziale, Italy)
- Fulvio Ferrante
(ASL Frosinone, 03100 Frosinone, Italy)
- Simona Gentile
(Direzione Generale per la Salute Regione Molise, 86100 Campobasso, Italy)
- Antonella Lavalle
(Direzione Generale per la Salute Regione Molise, 86100 Campobasso, Italy)
- Rossella Moscogiuri
(ASL Taranto, 74121 Taranto, Italy)
- Elena Mosele
(UOC Assistenza Farmaceutica Territoriale, Azienda ULSS 7 Pedemontana, 36061 Bassano del Grappa, Italy)
- Cataldo Procacci
(Dipartimento Farmaceutico ASL BAT, 76125 Trani, Italy)
- Davide Re
(ASL Teramo, 64100 Teramo, Italy)
- Fiorenzo Santoleri
(ASL Pescara, 65100 Pescara, Italy)
- Alessandro Roccia
(Gilead Sciences S.r.l., 20124 Milano, Italy)
- Franco Maggiolo
(ASST Papa Giovanni XXIII, 24127 Bergamo, Italy)
- Luca Degli Esposti
(CliCon S.r.l. Società Benefit—Health, Economics & Outcomes Research, 40137 Bologna, Italy)
Abstract
This real-world analysis conducted on administrative databases of a sample of Italian healthcare entities was aimed at describing the role of therapeutic pathways and drug utilization in terms of adherence, persistence, and therapy discontinuation in HIV-infected patients under antiretroviral therapies (ART) and Tenofovir Alafenamide (TAF)-based regimens on healthcare resource consumption and related direct healthcare costs. Between 2015 and 2019, adults (≥18 years) prescribed with TAF-based therapies were identified and characterized in the year prior to the first prescription (index-date) for TAF-based therapies and followed-up until the end of data availability. Overall, 2658 ART-treated patients were included, 1198 of which were under a TAF-based regimen. TAF-based therapies were associated with elevated percentages of adherence (83.3% patients with proportion of days covered, PDC > 95% and 90.6% with PDC > 85%) and persistence (78.5%). The discontinuation rate was low in TAF-treated patients, ranging from 3.3% in TAF-switchers to 5% in naïve. Persistent patients had lower overall mean annual healthcare expenditures (EUR 11,106 in persistent vs. EUR 12,380 in non-persistent, p = 0.005), and this trend was statistically significant also for costs related to HIV hospitalizations. These findings suggest that a better therapeutic management of HIV infection might result in positive clinical and economic outcomes.
Suggested Citation
Valentina Perrone & Melania Dovizio & Diego Sangiorgi & Margherita Andretta & Fausto Bartolini & Arturo Cavaliere & Andrea Ciaccia & Alessandro Chinellato & Alberto Costantini & Stefania Dell’Orco & F, 2023.
"Healthcare Resource Consumption and Related Costs in Patients on Antiretroviral Therapies: Findings from Real-World Data in Italy,"
IJERPH, MDPI, vol. 20(5), pages 1-12, February.
Handle:
RePEc:gam:jijerp:v:20:y:2023:i:5:p:3789-:d:1075402
Download full text from publisher
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:20:y:2023:i:5:p:3789-:d:1075402. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.